CORTCorcept Therapeutics Incorporated

$4B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+16.0% YoY

Gross Profit

$71M98.1% margin

Operating Income

$25M34.1% margin

Net Income

$20M27.9% margin

EPS (Diluted)

$0.17

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$25M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$329M

Total Liabilities

$31M

Stockholders' Equity

$298M

Cash & Equivalents

$226M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$62M	+16.0%
Gross Profit	$71M	$61M	+15.9%
Operating Income	$25M	$21M	+19.4%
Net Income	$20M	$18M	+10.9%

CORT Q2 2019 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena